Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: A pilot randomized clinical trial

Caspian Journal of Internal Medicine

Volumn 4, Issue 2, 2013, Pages 648-653

  Ziaee, Amir ^a   Vaezi, Amir Abbas ^a   Oveisi, Sonia ^a   Javadi, Amir ^a   Hashemipour, Sima ^a   Kazemifar, Amir Mohammad ^a  

^a QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Albuminuria; Angiotensin converting enzyme inhibitors (ACEIs); Diabetic nephropathy; Spironolactone

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; POTASSIUM; SPIRONOLACTONE;

ADD ON THERAPY; ADOLESCENT; ADULT; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ALBUMIN CREATININE RATIO; ALBUMINURIA; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LOW DRUG DOSE; MALE; PILOT STUDY; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL SYSTEM PARAMETERS; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84878982045     PISSN: 20086164     EISSN: 20086172     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. International Diabetes Federation. Diabetes Prevalence - Country Rankings. Availible at: http://www.allcountries. org/ranks/ diabetes-prevalence-country-ranks. Html. accessed Jan 20, 2010.
2. Davidson MB, Wong A, Hamrahian AH, Stevens M, Siraj ES. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. Endocr Pract. 2008; 14: 985-92.
3. Shahbazian H, Shahbazian H, Feghhi M, Ehsanpour A. A study on the effect of dual blocked of rennin and angiotensin systems in contoral of diabetic nephrophaty in patients with type 2 diabetic patients. Jundishapour Sci Med J 2009; 7: 90. [In Persian]
4. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-36.
5. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003; 14: 274-81.
6. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011; 7: 327-40.
7. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134: 370-9.
8. Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.
9. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-9.
10. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
11. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
12. Parving HH, Lehnert H, Brøchner-Mortensen J, et al. Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Ugeskr Laeger 2001; 163: 5519-24. [In Danish]
13. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601-6.
14. Lewis EJ. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2diabetes. Am J Hypertens 2002; 15, 123S-128S.
15. Mohamed RH, Abdel-Aziz HR, Abd El Motteleb DM, Abd El-Aziz TA. Effect of RAS inhibition on TGF-beta, renal function and structure in experimentally induced diabetic hypertensive nephropathy rats. Biomed Pharmacother 2009 Oct 24.
16. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-8.
17. Kidney Disease outcomes Qudity intiative (K/DOQI). K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic kidney Disease. Am J Kidney Dis 2004; 43: S1-290.
18. Saklayen MG, Gyebi LK, Tasosa J, Yap J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med 2008; 56: 714-9.
19. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-12.
20. Van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects onproteinuria, blood pressure and renal function. J Hypertens 2006; 24: 2285-92.
21. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-23.